Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01885338 · ClinicalTrials.gov registry record · Phase 1
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
A Phase 1 study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01885338: Completed Phase 1 study, sponsored by VA Greater Los Angeles Healthcare System.
NCT01885338 is a Phase 1 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01885338, a Phase 1 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will evaluate the effect of the dietary supplement N-acetylcysteine (NAC) on electrophysiologic (EEG) markers related to cognition, as well as performance on psychological tests measuring cognition. The primary hypothesis is that participants treated with NAC will show improvements in cognitive function, as measured by EEG and performance-based tests.
Primary Outcome
A passive attention auditory oddball paradigm will be used to assess MMN.
Interventions
- DRUG N-acetylcysteine (NAC)
- DRUG Inactive placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT01885338 record still lists
NCT01885338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which N-acetylcysteine (NAC) is the first listed.
NCT01885338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01885338 about?
NCT01885338 is a clinical study titled "N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia". This study will evaluate the effect of the dietary supplement N-acetylcysteine (NAC) on electrophysiologic (EEG) markers related to cognition, as well as performance on psychological tests measuring cognition. The primary hypothesis is that participants treated with NAC will show improvements in cog...
What is the current status of trial NCT01885338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01885338?
The interventions under investigation include: N-acetylcysteine (NAC) (DRUG), Inactive placebo capsule (DRUG).
Who is sponsoring clinical trial NCT01885338?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01885338's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia